BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:BioTTT001 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of BioTTT001\, from ClinicalTrials.gov estim
 ates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06763965-2397@assetmemo.bio
DTSTAMP:20261121T005440Z
DTSTART;VALUE=DATE:20270731
DTEND;VALUE=DATE:20270801
SUMMARY:BioTTT001: Phase 1/2 readout est. (NCT06763965)
DESCRIPTION:BioTTT001\, phase 1/2.\nStudy: Evaluating the Safety and Effica
 cy of BioTTT001 in Patients With Recurrent/Progressive High-grade Glioma.\
 nEstimated primary completion: 31 July 2027. This is a ClinicalTrials.gov 
 estimate\, not a confirmed readout date\, and it can move.\nDrug page: htt
 ps://assetmemo.bio/drug/biottt001#upcoming-events\nRegistry record: https:
 //clinicaltrials.gov/study/NCT06763965
URL:https://assetmemo.bio/drug/biottt001#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06283121-2397@assetmemo.bio
DTSTAMP:20261121T005440Z
DTSTART;VALUE=DATE:20271130
DTEND;VALUE=DATE:20271201
SUMMARY:BioTTT001: Phase 2 readout est. (NCT06283121)
DESCRIPTION:BioTTT001\, phase 2.\nStudy: A Clinical Study of BioTTT001 in C
 ombination With SOX and Toripalimab in Patients With Gastric Cancer\nEstim
 ated primary completion: 30 November 2027. This is a ClinicalTrials.gov es
 timate\, not a confirmed readout date\, and it can move.\nDrug page: https
 ://assetmemo.bio/drug/biottt001#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT06283121
URL:https://assetmemo.bio/drug/biottt001#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06283134-2397@assetmemo.bio
DTSTAMP:20261121T005440Z
DTSTART;VALUE=DATE:20271201
DTEND;VALUE=DATE:20271202
SUMMARY:BioTTT001: Phase 1 readout est. (NCT06283134)
DESCRIPTION:BioTTT001\, phase 1.\nStudy: A Clinical Study of BioTTT001 in C
 ombination With Toripalimab and Regorafenib in Patients With Colorectal Ca
 ncer\nEstimated primary completion: 1 December 2027. This is a ClinicalTri
 als.gov estimate\, not a confirmed readout date\, and it can move.\nDrug p
 age: https://assetmemo.bio/drug/biottt001#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT06283134
URL:https://assetmemo.bio/drug/biottt001#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07264569-2397@assetmemo.bio
DTSTAMP:20261121T005440Z
DTSTART;VALUE=DATE:20271230
DTEND;VALUE=DATE:20271231
SUMMARY:BioTTT001: Phase 1/2 readout est. (NCT07264569)
DESCRIPTION:BioTTT001\, phase 1/2.\nStudy: Evaluate the Safety\, Tolerabili
 ty\, Biodistribution Characteristics and Preliminary Efficacy of BioTTT001
 \nEstimated primary completion: 30 December 2027. This is a ClinicalTrials
 .gov estimate\, not a confirmed readout date\, and it can move.\nDrug page
 : https://assetmemo.bio/drug/biottt001#upcoming-events\nRegistry record: h
 ttps://clinicaltrials.gov/study/NCT07264569
URL:https://assetmemo.bio/drug/biottt001#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07472790-2397@assetmemo.bio
DTSTAMP:20261121T005440Z
DTSTART;VALUE=DATE:20280430
DTEND;VALUE=DATE:20280501
SUMMARY:BioTTT001: Phase 1 readout est. (NCT07472790)
DESCRIPTION:BioTTT001\, phase 1.\nStudy: A Study on the Novel Oncolytic Vir
 us Combined With PD-1 Inhibitor in the Treatment of Recurrent High-grade G
 lioma\nEstimated primary completion: 30 April 2028. This is a ClinicalTria
 ls.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pa
 ge: https://assetmemo.bio/drug/biottt001#upcoming-events\nRegistry record:
  https://clinicaltrials.gov/study/NCT07472790
URL:https://assetmemo.bio/drug/biottt001#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
